As we approach the first virtual ASCO meeting in the final week of May, we bring news of continued momentum in the area of oncology drug development. Whilst many trials have experienced disruption due to the COVID-19 crisis, regulatory bodies have remained focused on trying to prioritize oncology and complex diseases, with approvals this week granted in NSCLC and priority review designation to several therapies in development for cancer indications. We also bring you the latest in malaria epidemiology, understanding Alzheimer’s, cell therapy in MS, a novel method for monitoring autoimmune disorders, and the mapping of a key protein that the coronavirus uses to invade human cells, which may contribute to development of a vaccine.

Sign up for the Industry Watch newsletter and never miss a story again.

Yes, sign me up
FDA Grants Priority Review to Cancer Therapies

FDA Grants Priority Review to Cancer Therapies

The FDA granted priority review designation to several therapies in development for the treatment of cancer. Indications include metastatic solid tumors, large B-cell lymphoma, and NSCLC - where, despite advances, there remains an unmet need for additional innovative treatment options for patients.

Read more
Researchers Map Structure of Coronavirus "Spike" Protein

Researchers Map Structure of Coronavirus "Spike" Protein

Researchers worldwide are racing to develop potential vaccines and drugs to fight the new coronavirus, called SARS-Cov-2. Now, a group of researchers has figured out the molecular structure of a key protein that the coronavirus uses to invade human cells, potentially opening the door to the development of a vaccine, according to new findings.

Read more
What's New in Malaria Epidemiology?

What's New in Malaria Epidemiology?

To reduce malaria burden on a global scale, concerted global efforts will require enhanced surveillance of endemic transmission and imported malaria cases, mosquito vector populations, climate change, and human mobility, coupled with innovative prevention and control strategies.

Read more
Cell Therapy Repairs MS Damage & Restores Motor Functions in Mice

Cell Therapy Repairs MS Damage & Restores Motor Functions in Mice

A team of researchers at the University of Rochester Medical Center (URMC) is developing a method for regenerating myelin with progenitor glial cells. When they transplanted the cells into mouse models of MS, the cells transformed into new oligodendrocytes and restored myelin.

Read more
FDA Approves Tecentriq as Initial Treatment for Advanced NSCLC

FDA Approves Tecentriq as Initial Treatment for Advanced NSCLC

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) as an initial treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors produce high levels of the PD-L1 protein but have no alterations in the EGFR or ALK genes.

Read more
Air Pollution May Be Linked to Cognitive Decline in Older Adults

Air Pollution May Be Linked to Cognitive Decline in Older Adults

Research suggests that air pollution, particularly nitrogen dioxide, may be associated with memory loss, cognitive deficits, and a faster rate of cognitive decline among the elderly.

Read more
Novel Tool Developed to Diagnose and Monitor Autoimmune Disorders

Novel Tool Developed to Diagnose and Monitor Autoimmune Disorders

Researchers have developed a novel method for diagnosing and monitoring autoimmune disorders. Within a mere 25 minutes, a new test can measure the concentration of autoantibodies in human blood serum with extremely high sensitivity.

Read more

You have challenges. We have solutions.

Start a conversation